Skip to content

Archives of Clinical Neuropsychology

ISSN 0887-6177

3 papers in the library · 5 citations · publishing 2016-2024

Papers

A-118 Psychedelic Interventions for Neuropsychological Conditions

Archives of Clinical Neuropsychology August 17, 2022 Brian Peacock 3 citations

Psychedelic-assisted therapies, including ketamine, MDMA, and psilocybin, show promise for treating depression, anxiety, PTSD, and substance use disorders. This systematic review identified new potential applications for these therapies in neuropsychological conditions such as traumatic brain injury, stroke, autism spectrum disorder, and ADHD, while also noting contraindications when psychological disorders co-occur with neuropsychological conditions. The findings are synthesized to provide actionable clinical recommendations for practitioners.

B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult Populations

Archives of Clinical Neuropsychology September 12, 2024 James Perry, Cara C. Young, Julie Williams 1 citation

Microdosing psilocybin may offer an alternative treatment for adult ADHD with fewer side effects than standard stimulant medications, which act on dopamine and noradrenaline receptors and often cause significant adverse effects. This literature review examined research from several journals and found that psilocybin, acting primarily on serotonin receptors, not only produces fewer adverse effects but also provides a different therapeutic pathway when stimulants fail. The review highlights the neurological underpinnings—including 5-HT receptor involvement and neural plasticity—that may explain its potential success. Limitations of stimulant medications are also discussed. The findings suggest psilocybin microdosing could benefit adults seeking symptom management with reduced side effects.

B-56Investigation of Personality Change Following MDMA-Assisted Psychotherapy for Post Traumatic Stress Disorder

Archives of Clinical Neuropsychology August 31, 2016 Michael Wagner, Michael C. Mithoefer, Ann T. Mithoefer et al. 1 citation

In a Phase II clinical trial of MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD, increases in Openness and decreases in Neuroticism personality traits were linked to greater symptom reduction, regardless of treatment condition. Participants receiving MDMA showed the largest gains in Openness, which predicted lower PTSD severity. The authors propose that MDMA, combined with psychotherapy, may facilitate a reorganization of mental experience through altered brain pathways, rather than through psychological learning alone.